COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 29th March 2023)

This guideline covers the management of COVID-19 for babies, children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily. We are continually monitoring the evidence and updating the guideline as new information emerges. 29 March 2023: In the section on therapeutics for COVID-19 we: updated recommendations on baricitinib and remdesivir updated recommendations on casirivimab plus imdevimab, nirmatrelvir plus ritonavir, and tocilizumab, and replaced the recommendations on neutralising monoclonal antibodies and sarilumab with recommendations on sotrovimab and tocilizumab , in line with NICE technology appraisal guidance TA878.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news